Evidence map›Paper›PMID 42253317›Full record

ArticleMolecular syndromology2026

Role of Hyperlipidemia-Related

Gulcin Ozkara, Ezgi Irmak Aslan, Ozgur Selim Ser, Onur Kilicarslan, Ozlem Kucukhuseyin, Cem Bostan, Ahmet Yildiz, Oguz Ozturk, Hulya Yilmaz-Aydogan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular syndromology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Gulcin OzkaraDepartment of Medical Biology, Faculty of Medicine, Bezmialem Vakif University, Istanbul, Turkey.
Ezgi Irmak AslanDepartment of Molecular Medicine, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey.
Ozgur Selim SerDepartment of Cardiology, Turkish Ministry of Health Prof. Dr. Cemil Tascioglu City Hospital, Istanbul, Turkey.
Onur KilicarslanDepartment of Cardiology, Institute of Cardiology, Istanbul University-Cerrahpasa, Istanbul, Turkey.
Ozlem KucukhuseyinDepartment of Molecular Medicine, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey.
Cem BostanDepartment of Cardiology, Institute of Cardiology, Istanbul University-Cerrahpasa, Istanbul, Turkey.
Ahmet YildizDepartment of Cardiology, Institute of Cardiology, Istanbul University-Cerrahpasa, Istanbul, Turkey.
Oguz OzturkDepartment of Molecular Medicine, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey.
Hulya Yilmaz-AydoganDepartment of Molecular Medicine, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: This study aimed to evaluate the contribution of hyperlipidemia-related genetic variants, including protein convertase subtilisin/kexin type 9 ( Methods: A case-control design was applied, including male patients who developed restenosis (R; Results: Compared with the OS group, patients in the R group exhibited higher LDL cholesterol levels, increased prevalence of hyperlipidemia, and lower HDL cholesterol levels (all Conclusion: These findings suggest

Indexed as

Apolipoprotein EGenetic polymorphismHyperlipidemiaLow-density lipoprotein receptor-related protein 8 (APOE2R)Protein convertase subtilisin/kexin type 9Restenosis

Identifiers

PMID42253317
PMCPMC13241159

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.